(Q34357697)

1 August 2017

title

The effects of beta-adrenoceptor antagonists and levomepromazine on the metabolic ratio of debrisoquine (English)

1 reference

1 August 2017

Kallio J

1

1 reference

1 August 2017

Huupponen R

2

1 reference

1 August 2017

Seppälä M

3

1 reference

1 August 2017

Säkö E

4

1 reference

1 August 2017

Iisalo E

5

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 October 1990

1 reference

British Journal of Clinical Pharmacology

1 August 2017

published in

1 reference

1 August 2017

volume

30

1 reference

1 August 2017

issue

4

1 reference

1 August 2017

page(s)

638-643

1 reference

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368259

The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368259

Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368259

Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368259

Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368259

Elevation of thioridazine plasma levels by propranolol.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368259

Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368259

Effect of pindolol administration on serum levels of thioridazine, haloperidol, phenytoin, and phenobarbital.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368259

Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368259

Inhibitory effects of neuroleptics on debrisoquine oxidation in man

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368259

The impairment of lignocaine clearance by propranolol--major contribution from enzyme inhibition

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368259

Differential effect of continuous administration of beta-adrenoceptor antagonists on antipyrine and phenytoin clearance.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368259

Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368259

Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs

6 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.1990.TB03827.X

Clinical significance of the sparteine/debrisoquine oxidation polymorphism

21 January 2018

1 reference

12 December 2020

The effect of urine pH on debrisoquine phenotyping: application of an HPLC-method

1 reference

12 December 2020

Neuroloeptic effect on desipramine steady-state plasma concentratins

1 reference

12 December 2020

Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients

1 reference

12 December 2020

Interaction between antidepressants and perphenazine in psychiatric inpatients

1 reference

12 December 2020

Oxidation phenotype--a major determinant of metoprolol metabolism and response

1 reference

12 December 2020

Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs

1 reference

12 December 2020

Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade

1 reference

12 December 2020

In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase

1 reference

12 December 2020

Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin

1 reference

12 December 2020

Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites

1 reference

12 December 2020

Debrisoquine oxidative phenotyping and psychiatric drug treatment

1 reference

12 December 2020

10.1111/J.1365-2125.1990.TB03827.X

Identifiers

DOI

1 reference

1 August 2017

1 reference

1 August 2017

1 reference